Bryan Martin, MD
Medical Oncology · Great Falls, MTNPI 1689786519
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $870 of the $1,052 with a category attached, or 82.7%. It is spread thinly across 21 manufacturers, the largest accounting for just 14.4% — the pattern of someone who eats at a lot of different presentations.
Across 61 payments — averaging $17.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$152
- Amgen$129
- E.r. Squibb & Sons, L.L.C.$117
- Bristol Myers Squibb$95
- Novartis$80
- AbbVie$73
- plus $406 from 15 others
What the payments were for
- Food & beverage$87083%
- Education$18217%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 6 | $152 |
| Amgen | 8 | $129 |
| E.r. Squibb & Sons, L.L.C. | 8 | $117 |
| Bristol Myers Squibb | 6 | $95 |
| Novartis | 6 | $80 |
| AbbVie | 4 | $73 |
| Merck | 4 | $63 |
| Genentech, Inc. | 1 | $53 |
| Johnson & Johnson | 2 | $46 |
| Gilead | 3 | $41 |
| Pfizer | 2 | $30 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $27 |
| Eisai Inc. | 1 | $21 |
| Incyte Corporation | 1 | $19 |
| Beone Medicines USA, Inc. | 1 | $17 |
| Adaptive Biotechnologies Corporation | 1 | $16 |
| Alnylam Pharmaceuticals Inc. | 1 | $16 |
| Springworks Therapeutics, Inc. | 1 | $16 |
| Acrotech Biopharma Inc. | 1 | $15 |
| Regeneron Healthcare Solutions, Inc. | 1 | $13 |
| AstraZeneca | 1 | $11 |
How this compares
Too few medical oncology providers in Montanato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 29 | $628,829 |
| PomalystPomalidomide | 23 | $471,322 |
| IbrancePalbociclib | 23 | $374,860 |
| ImbruvicaIbrutinib | 24 | $294,550 |
| JakafiRuxolitinib Phosphate | 15 | $273,922 |
| CalquenceAcalabrutinib Maleate | 17 | $233,565 |
| BrukinsaZanubrutinib | 26 | $213,227 |
| XtandiEnzalutamide | 14 | $174,138 |
| Lenalidomide | 14 | $170,498 |
| Abiraterone Acetate | 24 | $70,986 |
| TasignaNilotinib Hcl | 13 | $61,227 |
| EliquisApixaban | 54 | $40,307 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $7,752 |
| Fondaparinux Sodium | 13 | $7,747 |
| Exemestane | 17 | $4,628 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $95 | $628,82929 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $117 | $471,32223 claims |
| PfizerIbrance, Eliquis | $30 | $415,16877 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $27 | $294,55024 claims |
| Incyte CorporationJakafi | $19 | $273,92215 claims |
| AstraZenecaCalquence | $11 | $233,56517 claims |
| Astellas Pharma US IncXtandi | $152 | $174,13814 claims |
| NovartisTasigna | $80 | $61,22713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few medical oncology providers in Montanaon file to place this against a meaningful peer group, so we don't.
Other medical oncology in Great Falls
- Justin ThomasBozeman$9K
- Kara SchenkBozeman$8K
- Kenneth MayBozeman$685
- Jose NessKalispell$351
- Robert JosephSidney$137
- James BurkeBillings$91
- Siobhan LynchMissoula$34
- Michael GoodmanRonan$14
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.